Skip to main content
. Author manuscript; available in PMC: 2022 Apr 7.
Published in final edited form as: Adv Exp Med Biol. 2021;1322:115–138. doi: 10.1007/978-981-16-0267-2_5

Table 5.6.

HBsAg inhibitors in development

Drug Route Company Clinical trial phase ClinicalTrials.gov identifier
REP 2139 Parenteral Replicor, Canada 2 NCT02726789
REP 2165 Parenteral Replicor, Canada 2 NCT02565719